Visus concludes subject enrolment in presbyopia therapy trial

Visus Therapeutics has completed participant enrolment in the Phase III BRIO-I clinical trial of Brimochol PF to treat presbyopia.

Emmetropic phakic and pseudophakic presbyopic participants were enrolled in the multi-centre, double-masked, safety and efficacy, randomised BRIO-I trial.